Comparison of BD BACTEC Plus Blood Culture Media versus VersaTREK REDOX

Size: px
Start display at page:

Download "Comparison of BD BACTEC Plus Blood Culture Media versus VersaTREK REDOX"

Transcription

1 JCM Accepts, published online ahead of print on February 0 J. Clin. Microbiol. doi:./jcm.01- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. 1 Comparison of BD BACTEC Plus Blood Culture Media versus VersaTREK REDOX Blood Culture Media for Detection of Bacterial Pathogens in Simulated Adult Blood Cultures Containing Therapeutic Concentrations Of Antibiotics Nancy S. Miller 1,*, Dagmar Rogan 1, Beverley L. Orr 1, Dana Whitney Department of Pathology and Laboratory Medicine 1 and Department of Pharmacy, Boston Medical Center, and Boston University School of Medicine, Boston, MA 0 Keywords: Blood culture media, blood culture systems, antibiotic inactivation Running head: Antibiotic inactivation in simulated blood cultures: BACTEC vs. VersaTREK Contact information for corresponding author: Nancy S. Miller, M.D. Division of Laboratory Medicine, Boston Medical Center East Newton Street, H00, Boston, MA 0 nancy.miller@bmc.org Downloaded from on September 1, 01 by guest 1 Phone: (1) -0, Fax: (1) - 1

2 Abstract Antibiotic neutralization in blood culture media from two automated systems was evaluated by measuring recovery of organisms and time to detection in simulated cultures. Overall, BD BACTEC Plus Media (BACTEC FX system) outperformed TREK 0 ml REDOX media (VersaTREK system), although results suggest a relative rather than an absolute increased recovery for BACTEC. Blood samples taken from patients on antibiotic therapy can delay or prevent the detection of bacteremia in automated blood culture systems. BD BACTEC TM Plus Media on the new BACTEC TM FX and the incumbent 000 series blood culture systems (BD Diagnostics, Sparks, MD) utilize cationic exchange and nonionic adsorbent resins to remove antibiotics from blood samples. In contrast, 0 ml REDOX media on the VersaTREK blood culture system (TREK Diagnostics, Cleveland, OH) relies on an optimal 1: blood:broth dilution to neutralize antibiotic effects. Few recent studies (1,,) have compared VersaTREK media to BACTEC media for antibiotic inactivation. This in vitro study compared the ability of each system and media to neutralize various antibiotics at trough (T), mid (M), and peak (P) simulated therapeutic serum concentrations when tested against susceptible bacterial challenge organisms. BACTEC Plus /F (0 ml) media (BACTEC) and TREK 0A aerobic REDOX 1 (0 ml) media (TREK) were used for all challenge organisms. BACTEC Plus Anaerobic/F ( ml) media and TREK 0N anaerobic REDOX media (0 ml) were also used for Streptococcus oralis and Streptococcus pneumoniae. Stock solutions of each antibiotic (0.1 Downloaded from on September 1, 01 by guest

3 ml) were potency-adjusted to simulate T, M, and P serum concentrations based on ml of blood per media bottle. Antibiotics were chosen for clinical relevance and serum concentrations were based on current dosing recommendations. Final antibiotic concentrations (T, M, and P levels in µg/ml) were as follows: ampicillin (, 1, ), cefepime (, 1, 1), ceftriaxone (1,, 0), levofloxacin (1.,., 1), piperacillin/tazobactam (1./0., 1/, /), and vancomycin (,, 0). These were tested against ATCC challenge strains as indicated in Tables 1 and. Concentrations for each antibiotic were per manufacturer or calculated from antibiotic half-life and based on recommended doses for the treatment of severe infections in an average weight adult with normal renal function. A susceptible minimal inhibitory concentration (MIC) for each antibiotic was confirmed by replicate testing using Etest agar gradient method (biomérieux SA) for each relevant bacterial species tested against that drug. Media bottles were inoculated with ml banked whole blood (Interstate Blood Bank, Inc., Memphis, Tennessee) not more than days old, 0.1 ml potency-adjusted antibiotic (or saline for controls) and 0.1 ml challenge organism suspended in 0.% saline containing between 0 colony forming units (inocula confirmed by colony count plating). Inoculated bottles were incubated per -day protocol on their respective instruments. Each organism/antibiotic concentration was run concurrently in triplicate for a total of two trial replications on two separate days. Antibiotic neutralization was measured as the percent recovery of organisms and time to detection (TTD) in seeded, antibiotic-containing blood culture bottles. Data are reported as aggregate results from all trials and were analyzed using SAS (SAS Institute, Cary, NC). Comparison of organism recovery was performed using Fisher s exact test with a P-value < 0.0 to indicate statistical significance. Downloaded from on September 1, 01 by guest

4 Overall recovery of organisms by BACTEC was.% (1/) and 1.% (/) for TREK. This difference was statistically significant (p<0.0001). Results were further stratified by media type and antibiotic concentrations (Table 1). Differences were statistically significant in favor of BACTEC. There were no instances for which both systems performed equally well at recovering challenge organisms for all concentrations of a specific antibiotic (Table ). Significant differences between the two systems were observed for specific concentrations of agents. For all concentrations of vancomycin, organism recovery by BACTEC was significantly different since no challenge organisms, including S. aureus, were recovered by TREK. For all concentrations of ceftriaxone both systems failed to recover any S. pneumoniae or S. oralis despite acceptable growth in control bottles. Results are further tabulated in Table. Results showed BACTEC Plus media to be significantly more efficient at recovery of challenge organisms in the presence of antibiotics as compared to TREK REDOX media. For both systems when percent organism recovery was not 0% it decreased with increasing amounts of antibiotic, consistent with expectations (,, ). (Two outliers to this are evident in Table for TREK media: for ampicillin there was recovery of E. faecalis at trough and peak but none at mid concentration; for vancomycin there was recovery of E. faecalis only at peak concentration of vancomycin. For each of these apparent paradoxes a clerical error or variation in bottle inoculation (pipetting) cannot be excluded). The current study design intentionally mirrored one used by Flayhart et al. () for their comparison of BACTEC to BacT/Alert media. But we used the BACTEC FX instrument and the 0 ml Plus /F bottle (instead of the 0 cabinet and ml Plus /F bottle); slightly different T, M, and P serum concentrations of antibiotics were based on our clinical Downloaded from on September 1, 01 by guest

5 pharmacist s calculations. Our results are similar to those reported by Flayhart et al. However, our BACTEC s overall recovery of organisms (.%) and recovery of organisms from test bottles (.%) differs from Flayhart et al. (.1% and.%, respectively) and is likely attributable to differences in MIC, or the number of organisms or antibiotics used. Where calculated serum concentrations were the same and results could be equitably compared both our study and Flayhart et al. showed equivalent or enhanced recovery of organisms for BACTEC versus the comparator system (). Notable variations in BACTEC performance between the two studies include S. pneumoniae in the presence of ampicillin, S. aureus (MSSA) in the presence of vancomycin, and E. coli and P. aeruginosa in the presence of cefepime. In each instance, BACTEC recovered a higher percentage of organisms in Flayhart et al. than in the present study. However, in our study BACTEC recovered more S. pneumoniae in the presence of vancomycin than it did in Flayhart et al. We used lower calculated mid-level antibiotic concentrations than did Flayhart et al., but our recovery rates for BACTEC were lower. These differences are possibly due to variations in inoculum at extremes of the allowed range or differences in antibiotic MIC (data unable to be compared). In the present study BACTEC also provided an advantage over TREK regarding overall TTD (Table 1). Delay in detection time was generally dependent on increased concentration of antibiotic, consistent with other studies (, ). Divergent results seem due to a majority of isolates not growing within five days at the higher drug concentration. LaBombardi et al. () also noted discrepancies between their own incomplete resinadsorption results and other reports citing apparent resin-binding and successful organism recovery including those cited by Flayhart et al. Results for simulated studies (,,) are not always concordant with controlled clinical trials (,, 1). But two seeded studies (1, ) and one Downloaded from on September 1, 01 by guest

6 limited prospective study () have favored BACTEC media versus TREK media in their respective scenarios of antibiotic or other antimicrobial neutralization Simulated trials do not account for any advantages that might be conferred to TREK by patient serum-related antibiotic neutralizing factors in the context of broth dilution; to date this has not been thoroughly evaluated by controlled clinical studies. Our findings suggest a relative rather than absolute advantage for the BACTEC system as compared to TREK, within the limitations of a simulated study. Time of draw for blood cultures should remain an important clinical consideration, to ensure that samples are taken at the lowest possible serum levels of antibiotics in order to facilitate optimal recovery of bloodstream pathogens. We acknowledge Christopher Amantia and his colleagues in the BMC Clinical Microbiology Laboratory for their technical help in conducting this study. We thank Dr. Gheorghe Doros (Boston University Department of Biostatistics) for his analysis of the study data. Material support for this study was provided by BD Diagnostics, Sparks, MD. Authors Disclosure Statement The authors report no conflict of interest in relation to this manuscript. References Downloaded from on September 1, 01 by guest Dam, L.M., S.W. Eisinger, P.D. Stamper, N. Epie, K.C. Carroll, and S. Riedel. 0. Comparison of the BACTEC Plus blood culture media to the VersaTREK REDOX blood culture media for detection of yeast in seeded blood culture specimens containing therapeutic levels of

7 antifungal agents, abstr. C-0, Abstr.1th Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, San Diego, CA DiPersio, J. and H. Bonilla. 0. Comparison of BACTEC Plus /F and VersaTREK REDOX 1 Blood Culture Media for the Recovery of S. aureus from Patients with Suspected Persistent Bacteremia, abstr. C-, Abstr.1th Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, San Diego, CA.. DiPersio, J., L. DiPersio, and J. Beach. 00. Recovery of Staphylococcus aureus from BACTEC PLUS and VersaTrek REDOX 1 blood culture media with increasing concentrations of vancomycin, daptomycin, or linezolid, abstr. D-0, Abstr. th Ann. Intersci. Conf. Antimicrob. Agents Chemother. / th Ann. Infect. Dis. Soc. Amer., Washington, D.C.. Flayhart, D., A.P. Borek, T. Wakefield, J. Dick, and K.C. Carroll. 00. Comparison of BACTEC PLUS blood culture media to BacT/Alert FA blood culture media for detection of bacterial pathogens in samples containing therapeutic levels of antibiotics. :1 1.. Jorgensen, J. H., S. Mirrett, L. C. McDonald, P. R. Murray, M. P. Weinstein, J. Fune, C. W. Trippy, M. Masterson, and L. B. Reller. 1. Controlled clinical laboratory comparison of BACTEC Plus aerobic/f resin medium with BacT/Alert aerobic FAN medium for detection of bacteremia and fungemia. J. Clin. Microbiol. :.. LaBombardi, V., J. Sotos, S. Allen, and N. Sullivan. 00. Resins do not adsorb all antibiotics at peak serum concentrations, especially the newer beta-lactam antibiotics. American Society for Microbiology. th ASM General Meeting, May 1-1, Philadelphia, PA. Abstract C-0. Downloaded from on September 1, 01 by guest

8 . Pohlman, J. K., B. A. Kirkley, K. A. Easley, B. A. Basille, and J. A. Washington. 1. Controlled clinical evaluation of BACTEC Plus /F and BacT/Alert FAN bottles for detection of bloodstream infections. J. Clin. Microbiol. : Spaargaren, J., C. P. A. van Boren, and G. P. Voorn. 1. Effectiveness of resins in neutralizing antibiotic activities in BACTEC Plus /F culture medium. J. Clin. Microbiol. :1.. Vigano, E.F., E. Vasconi, C. Agrappi, P. Clerici. 00. Use of simulated blood cultures for time to detection comparison between BacT/ALERT and BACTEC 0 blood culture systems. Diagn. Microbiol. Infect. Dis. : 0.. Vigano, E. F., E. Vasconi, C. Agrappi, P. Clerici, and P. Melloni. 00. Use of simulated blood cultures for antibiotic effect on time to detection of the two blood culture systems BacT/Alert and BACTEC 0. New Microbiol. :.. Washington, J. A., II, and D. M. Ilstrup. 1. Blood cultures: issues and controversies. Rev. Infect. Dis. : Ziegler, R., I. Johnscher, P. Martus, D. Lenhardt, and H.-M. Just. 1. Controlled clinical laboratory comparison of two supplemented aerobic and anaerobic media used in automated blood culture systems to detect bloodstream infections. J. Clin. Microbiol. :-1. Downloaded from on September 1, 01 by guest

9 Table 1. Overall Organism recovery and average time-to-detection (TTD) by media type and antibiotic concentrations BACTEC TREK p value score Media Drug (T; M; P) 1 Statistic Total Control (%) Trough (%) Mid (%) Peak (%) Control (%) Trough (%) Mid (%) Peak (%) C T M P Anaerobic Anaerobic Ampicillin (;1;) Cefepime (;1;1) Recovered (0) (.) 0 (.) (.) (0) (1.) (.) (.) <0.001 <0.001 <0.001 AVG TTD Combined 1/ (.) /() (1.) Recovered 0 0 (0) 1 (.) 1 (.) 1 (0) (.) (0) (1.) 0 (0) < <0.001 AVG TTD NA Combined Overall (0) 0/0 (.) 1/ (.) (.1) /0 (1.) / (1.) Recovered (0) (0) (.) (.) (0) (.) 0 (0) 1 (.1) AVG TTD NA 0. Recovered (0) (.) 1 (1.) 0 (0) (.) 0 (0) 0 (0) 0 (0) AVG TTD NA 1. NA NA NA Recovered 1 1 (0) (0) () 0 (0) 1 (0) (0) 0 (0) 0 (0) AVG TTD NA 1.. NA NA Recovered (0) 0 (0) 0 (0) 0 (0) (0) 0 (0) 0 (0) 0 (0) Ceftriaxone AVG TTD 1.1 NA NA NA 1. NA NA NA Anaerobic (1;;0) Recovered (0) 0 (0) 0 (0) 0 (0) (0) 0 (0) 0 (0) 0 (0) AVG TTD 1. NA NA NA 1. NA NA NA Recovered 1 1 (0) 1 (.) (.) (.) (0) 1 (.) (.) 0 (0) Levofloxacin AVG TTD NA Anaerobic (1.;.;1) Recovered (0) (0) (0) (0) (0) (0) (.) 0 (0) AVG TTD NA Piperacillin/ Tazobactam Recovered (1./0.; 1/; 1 1 (0) 1 (0) () (.) 1 (0) 1 (0) (1.) 0 (0) /) AVG TTD Recovered (0) (0) (1.) 1 (.) (0) 0 (0) 0 (0) 1 (.) <0.001 <0.001 <0.001 Vancomycin AVG TTD NA NA. Anaerobic (;;0) Recovered (0) (0) (0) (0) (0) 0 (0) 0 (0) 0 (0) AVG TTD NA NA NA 1 Antimicrobial concentration (ug/ml) for Trough. Mid, and Peak levels C=Control; T=Trough' M=Mid; P=Peak. in hours; values rounded to the nearest decimal. Downloaded from on September 1, 01 by guest

10 1 Table 1: Overall organism recovery and average-time-to-detection (TTD) by media type and antibiotic concentrations 1 Antibiotic concentration (ug/ml) for Trough, Mid, and Peak levels C = Control; T = Trough; M = Mid; P = Peak TTD in hours, values rounded to the nearest decimal Table : Microorganism specific recovery by antibiotic concentration 1 Microoganism ATCC catalog numbers: Streptococcus pneumoniae ATCC 1; Streptococcus oralis ATCC ; Enterococcus faecalis ATCC ; Staphylococcus aureus ATCC (MSSA); Staphylococcus aureus ATCC 00 (MRSA); Escherichia coli ATCC ; Pseudomonas aeruginosa ATCC. Downloaded from on September 1, 01 by guest

11 Table : Microorganism specific recovery by antibiotic concentration Trough (%) Mid (%) Peak (%) Trough (%) Mid (%) Peak (%) Drug Microorganism 1 * 1* * * 1* * Ampicillin Cefepime Ceftriaxone Streptococcus pneumoniae (0) 1 (1.) 0 (0) 0 (0) 0 (0) 0 (0) Streptococcus oralis (.) (0) 1 (1.) 1 (1.) 0 (0) 0 (0) Enterococcus faecalis (0) (0) (.) (0) 0 (0) 1 (.) Escherichia coli Total BACTEC Antimicrobial concentration (ug/ml)* * 1* 1* * 1* 1* 1 (1.) 0 (0) 0 (0) 1 (1.) 0 (0) 0 (0) Pseudomonas aeruginosa (.) (0) 0 (0) (.) 0 (0) 0 (0) 1* * 0* 1* * 0* Streptococcus pneumoniae 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Streptococcus oralis 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1.*.* 1* 1.*.* 1* Streptococcus pneumoniae 1 1 (0) 1 (0) 1 (0) 1 (0) (1.) 0 (0) Levofloxacin Escherichia coli (.) 0 (0) 0 (0) 1 (1.) 0 (0) 0 (0) Pseudomonas aeruginosa (0) (.) 1 (1.) (0) (.) 0 (0) 1./0.* 1/* /* 1./0.* 1/* /* Piperacillin/ Escherichia coli (0) (.) (0) (0) (.) 0 (0) Tazobactam Pseudomonas aeruginosa (0) (.) 1 (1.) (0) 0 (0) 0 (0) * * 0* * * 0* Staphylococcus aureus MSSA (0) (.) 1 (1.) 0 (0) 0 (0) 0 (0) Staphylococcus aureus MRSA (0) (0) (0) 0 (0) 0 (0) 0 (0) Vancomycin Streptococcus pneumoniae (0) (0) (0) 0 (0) 0 (0) 0 (0) Streptococcus oralis 1 1 (0) 1 (0) 1 (0) 0 (0) 0 (0) 0 (0) Enterococcus faecalis (0) (0) (0) 0 (0) 0 (0) 1 (.) 1 Microoganism ATCC catalog numbers: Streptococcus pneumoniae ATCC 1; Streptococcus oralis ATCC ; Enterococcus faecalis ATCC ; Staphylococcus aureus ATCC (MSSA); Staphylococcus aureus ATCC 00 (MRSA); Escherichia coli ATCC ; Pseudomonas aeruginosa ATCC. TREK Antimicrobial concentration (ug/ml)* Downloaded from on September 1, 01 by guest

Tel: Fax:

Tel: Fax: CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.

More information

against Clinical Isolates of Gram-Positive Bacteria

against Clinical Isolates of Gram-Positive Bacteria ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,

More information

Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals

Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.

More information

2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)

2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time) Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according

More information

17June2017. Parampal Deol, Ph.D, MBA Senior Director, R&D Microbiology North America

17June2017. Parampal Deol, Ph.D, MBA Senior Director, R&D Microbiology North America RAPID DETECTION OF BACTERIAL CONTAMINANTS IN PLATELET COMPONENTS: COMPARISON OF TIME TO DETECTION BETWEEN THE BACT/ALERT 3D AND THE BACT/ALERT VIRTUO SYSTEMS. 17June2017 Parampal Deol, Ph.D, MBA Senior

More information

Guidelines for Laboratory Verification of Performance of the FilmArray BCID System

Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory

More information

TEST REPORT. Client: M/s Ion Silver AB. Loddekopinge. Sverige / SWEDEN. Chandran. min and 30 min. 2. E. coli. 1. S. aureus

TEST REPORT. Client: M/s Ion Silver AB. Loddekopinge. Sverige / SWEDEN. Chandran. min and 30 min. 2. E. coli. 1. S. aureus TEST REPORT TEST TYPE: Liquid Suspension Time Kill Study -Quantitative Test Based On ASTM 2315 TEST METHOD of Colloidal Silver Product at Contact time points: 30 sec, 1 min, 2 min, 5 min, 10 min, 15 min

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

Background and Plan of Analysis

Background and Plan of Analysis ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification

More information

Antimicrobial Pharmacodynamics

Antimicrobial Pharmacodynamics Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062

More information

MICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ

MICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association

More information

The Impact of meca Gene Testing and Infectious Diseases Pharmacists. Intervention on the Time to Optimal Antimicrobial Therapy for ACCEPTED

The Impact of meca Gene Testing and Infectious Diseases Pharmacists. Intervention on the Time to Optimal Antimicrobial Therapy for ACCEPTED JCM Accepts, published online ahead of print on 7 May 2008 J. Clin. Microbiol. doi:10.1128/jcm.00801-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information

More information

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2. AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony

More information

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance

More information

Antimicrobial Stewardship Strategy: Antibiograms

Antimicrobial Stewardship Strategy: Antibiograms Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide

More information

Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?

Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

Barriers to Intravenous Penicillin Use for Treatment of Nonmeningitis

Barriers to Intravenous Penicillin Use for Treatment of Nonmeningitis JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Test Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants

Test Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants Study Title Antibacterial Activity and Efficacy of E-Mist Innovations' Electrostatic Sprayer Product with Multiple Disinfectants Method Modified Association of Analytical Communities Method 961.02 Modified

More information

Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants.

Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants. Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants. C. difficile rarely causes problems, either in healthy adults or in infants.

More information

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical

More information

6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS

6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS 6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS 6.1 INTRODUCTION Microorganisms that cause infectious disease are called pathogenic microbes. Although

More information

EUCAST recommended strains for internal quality control

EUCAST recommended strains for internal quality control EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC

More information

ANTIMICROBIAL TESTING. with ALKA VITA (ALKAHYDROXY ) ESCHERICHIA COLI STAPHYLOCOCCUS AUREUS (MRSA) PSEUDOMONA AERUGINOSA ENTEROBACTER CLOACAE

ANTIMICROBIAL TESTING. with ALKA VITA (ALKAHYDROXY ) ESCHERICHIA COLI STAPHYLOCOCCUS AUREUS (MRSA) PSEUDOMONA AERUGINOSA ENTEROBACTER CLOACAE ANTIMICROBIAL TESTING with ALKA VITA (ALKAHYDROXY ) on ESCHERICHIA COLI STAPHYLOCOCCUS AUREUS (MRSA) PSEUDOMONA AERUGINOSA ENTEROBACTER CLOACAE FINAL RESULTS OF ANTIBACTERIAL TESTS IN VITRO WITH THE PRODUCT

More information

CME/SAM. Validation and Implementation of the GeneXpert MRSA/SA Blood Culture Assay in a Pediatric Setting

CME/SAM. Validation and Implementation of the GeneXpert MRSA/SA Blood Culture Assay in a Pediatric Setting Microbiology and Infectious Disease / Xpert MRSA/SA in Pediatric Blood Cultures Validation and Implementation of the GeneXpert MRSA/SA Blood Culture Assay in a Pediatric Setting David H. Spencer, MD, PhD,

More information

Antimicrobial Susceptibility Testing: The Basics

Antimicrobial Susceptibility Testing: The Basics Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The

More information

What s new in EUCAST methods?

What s new in EUCAST methods? What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests

More information

Title: N-Acetylcysteine (NAC) Mediated Modulation of Bacterial Antibiotic

Title: N-Acetylcysteine (NAC) Mediated Modulation of Bacterial Antibiotic AAC Accepts, published online ahead of print on June 00 Antimicrob. Agents Chemother. doi:0./aac.0070-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are

More information

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be

More information

Received 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004

Received 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2004, p. 3112 3118 Vol. 48, No. 8 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.8.3112 3118.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.

More information

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine 2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose

More information

OPAT discharge navigator and laboratory monitoring Select OPAT button for ALL patients that discharge on intravenous antimicrobials

OPAT discharge navigator and laboratory monitoring Select OPAT button for ALL patients that discharge on intravenous antimicrobials Clinical Monitoring of Outpatient Parenteral Antimicrobial Therapy (OPAT) and Selected Oral Antimicrobial Agents Adult Inpatient/Ambulatory Clinical Practice Guideline Appendix A. Coordinating an OPAT

More information

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXVII NUMBER 6 July 2012 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine B. Dowell SM, MLS (ASCP); Sarah K. Parker, MD; James K. Todd, MD Each year the Children s Hospital Colorado

More information

Quality assurance of antimicrobial susceptibility testing

Quality assurance of antimicrobial susceptibility testing Quality assurance of antimicrobial susceptibility testing Derek Brown Routine quality control Repeated testing of controls in parallel with tests to ensure that the test system is performing reproducibly

More information

Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing

Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Quality Assurance of antimicrobial susceptibility testing Derek Brown EUCAST Scientific Secretary ESCMID Postgraduate Education Course, Linz, 17 September 2014 Quality Assurance The total process by which

More information

The Nuts and Bolts of Antibiograms in Long-Term Care Facilities

The Nuts and Bolts of Antibiograms in Long-Term Care Facilities The Nuts and Bolts of Antibiograms in Long-Term Care Facilities J. Kristie Johnson, Ph.D., D(ABMM) Professor, Department of Pathology University of Maryland School of Medicine Director, Microbiology Laboratories

More information

Principles of Antimicrobial Therapy

Principles of Antimicrobial Therapy Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1

More information

Reassessment of the "Class" Concept of Disk Susceptibility Testing

Reassessment of the Class Concept of Disk Susceptibility Testing Reassessment of the "Class" Concept of Disk Susceptibility Testing Disks versus Minimal Inhibitory Concentrations with Eleven Cephalosporins ARTHUR L. BARRY, PH.D., CLYDE THORNSBERRY, PH.D., RONALD N.

More information

International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.

International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED

More information

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

Routine internal quality control as recommended by EUCAST Version 3.1, valid from Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus

More information

Antimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services

Antimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO

More information

Susceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System

Susceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System Polish Journal of Microbiology 2005, Vol. 54, No 4, 311 316 Susceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System EL BIETA STEFANIUK*, AGNIESZKA MRÓWKA

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

Determination of antibiotic sensitivities by the

Determination of antibiotic sensitivities by the Journal of Clinical Pathology, 1978, 31, 531-535 Determination of antibiotic sensitivities by the Sensititre system IAN PHILLIPS, CHRISTINE WARREN, AND PAMELA M. WATERWORTH From the Department of Microbiology,

More information

ENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN

ENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN ENTEROCOCCI April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic antimicrobial susceptibility principles and resistance mechanisms for Enterococcus Describe issues surrounding AST

More information

EARS Net Report, Quarter

EARS Net Report, Quarter EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased

More information

EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING

EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production

More information

microbiology testing services

microbiology testing services microbiology testing services You already know Spectra Laboratories for a wide array of dialysis-related testing services. Now get to know us for your microbiology needs. As the leading provider of renal-specific

More information

In Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone

In Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone

More information

The Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3. Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University

The Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3. Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University The Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3 Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University Tae-yoon Choi ABSTRACT BACKGROUND: The use of disinfectants

More information

Antimicrobial susceptibility testing of Campylobacter jejuni and C. coli. CRL Training course in AST Copenhagen, Denmark 23-27th Feb.

Antimicrobial susceptibility testing of Campylobacter jejuni and C. coli. CRL Training course in AST Copenhagen, Denmark 23-27th Feb. Antimicrobial susceptibility testing of Campylobacter jejuni and C. coli CRL Training course in AST Copenhagen, Denmark 23-27th Feb. 2009 Methodologies E-test by AB-biodisk A dilution test based on the

More information

Drive More Efficient Clinical Action by Streamlining the Interpretation of Test Results

Drive More Efficient Clinical Action by Streamlining the Interpretation of Test Results White Paper: Templated Report Comments Drive More Efficient Clinical Action by Streamlining the Interpretation of Test Results Background The availability of rapid, multiplexed technologies for the comprehensive

More information

Collecting and Interpreting Stewardship Data: Breakout Session

Collecting and Interpreting Stewardship Data: Breakout Session Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline

More information

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

Compliance of manufacturers of AST materials and devices with EUCAST guidelines Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The

More information

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America

More information

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

Compliance of manufacturers of AST materials and devices with EUCAST guidelines Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The

More information

DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams

DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for

More information

Original Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**

Original Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.** Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,

More information

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin

More information

New Drugs for Bad Bugs- Statewide Antibiogram

New Drugs for Bad Bugs- Statewide Antibiogram New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda

More information

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA

More information

GeNei TM. Antibiotic Sensitivity. Teaching Kit Manual KT Revision No.: Bangalore Genei, 2007 Bangalore Genei, 2007

GeNei TM. Antibiotic Sensitivity. Teaching Kit Manual KT Revision No.: Bangalore Genei, 2007 Bangalore Genei, 2007 GeNei Bacterial Antibiotic Sensitivity Teaching Kit Manual Cat No. New Cat No. KT68 106333 Revision No.: 00180705 CONTENTS Page No. Objective 3 Principle 3 Kit Description 4 Materials Provided 5 Procedure

More information

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How

More information

Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems

Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective

More information

Antimicrobial Susceptibility Testing: Advanced Course

Antimicrobial Susceptibility Testing: Advanced Course Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to

More information

General Approach to Infectious Diseases

General Approach to Infectious Diseases General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus

An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Article ID: WMC00590 ISSN 2046-1690 An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Author(s):Dr. K P Ranjan, Dr. D R Arora, Dr. Neelima Ranjan Corresponding

More information

UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients

UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management

More information

Should we test Clostridium difficile for antimicrobial resistance? by author

Should we test Clostridium difficile for antimicrobial resistance? by author Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first

More information

LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES

LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES Goodbye to the Antibiotic Era? Glenn D. Bedsole, MD, FACP Infectious Disease Consultant 1. Be able to list 6 examples of resistant bacteria that present

More information

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria

More information

Staph Cases. Case #1

Staph Cases. Case #1 Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling

More information

Pathogens and Antibiotic Sensitivities in Post- Phacoemulsification Endophthalmitis, Kaiser Permanente, California,

Pathogens and Antibiotic Sensitivities in Post- Phacoemulsification Endophthalmitis, Kaiser Permanente, California, Pathogens and Antibiotic Sensitivities in Post- Phacoemulsification Endophthalmitis, Kaiser Permanente, California, 2007-2012 Geraldine R. Slean, MD, MS 1 ; Neal H. Shorstein, MD 2 ; Liyan Liu, MD, MS

More information

Effeet on Bacterial Growth

Effeet on Bacterial Growth ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 17, p. 36-366 Copyright ( 17 American Society for Microbiology Vol., No. 5 Printed in U.S.A. Automatic Radiometric Measurement of Antibiotic Effeet on Bacterial

More information

MRSA surveillance 2014: Poultry

MRSA surveillance 2014: Poultry Vicky Jasson MRSA surveillance 2014: Poultry 1. Introduction In the framework of the FASFC surveillance, a surveillance of MRSA in poultry has been executed in order to determine the prevalence and diversity

More information

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance

More information

Streptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance

Streptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance Streptococcus pneumoniae Oxacillin µg as screen for beta-lactam resistance Version 6. June Streptococcus pneumoniae and zone diameter correlates The following histograms present inhibition zone diameter

More information

SYMMETRY ANTIMICROBIAL FOAMING HANDWASH with 0.3% PCMX Technical Data

SYMMETRY ANTIMICROBIAL FOAMING HANDWASH with 0.3% PCMX Technical Data 408 SYMMETRY ANTIMICROBIAL FOAMING HANDWASH with 0.3% PCMX Technical Data Physical Properties Active Ingredient: Chloroxylenol (PCMX) 0.3% Appearance: Clear, Amber Solution Fragrance: Floral Form: Liquid

More information

Evaluation of the BIOGRAM Antimicrobial Susceptibility Test System

Evaluation of the BIOGRAM Antimicrobial Susceptibility Test System JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1985, p. 793-798 0095-1137/85/110793-06$02.00/0 Copyright 1985, American Society for Microbiology Vol. 22, No. 5 Evaluation of the BIOGRAM Antimicrobial Susceptibility

More information

Mark Your Calendars Now! Next Event Ships: September 14, 2015

Mark Your Calendars Now! Next Event Ships: September 14, 2015 www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 Shipment Date: June 15, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261 x51 or amanda.weiss@slh.wisc.edu.

More information

on February 12, 2018 by guest

on February 12, 2018 by guest AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of

More information

STAPHYLOCOCCI: KEY AST CHALLENGES

STAPHYLOCOCCI: KEY AST CHALLENGES Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu STAPHYLOCOCCI: KEY AST CHALLENGES THE CHALLENGES detection of penicillin resistance detection

More information